Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ. “Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.” Urology October 2011; 78: 970 .e 15-20. PMID: 21820706. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/
Loeb S. “Prostate Cancer: Is PSA Velocity Useful?” Nature Reviews Urology, June 2009; 6: 305. Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408
Loeb S, Chan DW, Sokoll L, Kan D, Mikolajczyk SD, Maggiore J, Mondo DM, Griffin CR, and Catalona WJ. “PSA Standardization Bias Could Affect Clinical Decision-making.” Journal of Urology, November 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18801532
Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ. “Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.” Journal of Urology, August 2010; 184: 501. Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408
Loeb S. “Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use.” BJU International June 2012; 109: 1785-6. PMID: 22040375. Link: http://www.ncbi.nlm.nih.gov/pubmed/22040375
Loeb S. “Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?” European Urology 2014 Nov epub. PMID: 25465339. Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339
Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ. “Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?” Journal of Urology, January 2007; 177: 102. Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013
Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ. “Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression” Urology, July 2006; 68: 99. Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410
Loeb S and Carter HB. “Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.” European Urology, February 2009; 55: 523. Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535
Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ. “Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.” Urology December 2007; 70: 1117. Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030
Helfand BT, Loeb S, Kan D, Catalona WJ. “Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.” BJU International, June 2010 epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552
Loeb S, Van den Heuvel S, Zhu X, Bangma CH, Schroder FH, and Roobol MH. “Reply from the Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy- Thou Shall Think Twice.” Eur Urol. In press. DOI:10.1016/j.eururo.2012.01.055: Considerations for Prostate Biopsy Decisions.” European Urology; 2012 March 8 epub. Link: http://www.europeanurology.com/article/S0302-2838%2812%2900307-7/fulltext/reply-from-authors-re-alexandre-r-zlotta-robert-k-nam-to-biopsy-or-not-to-biopsy-x02014-thou-shall-think-twice-eur-urol-2012-61-1115-x02013-7
Loeb S. “Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’” Urology Practice 2014 May; 1: 20.
Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB. “The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.” European Urology, November 2008 54: 978. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/
Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ. “Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” Urology, June 2007; 69: 1143. Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203
Loeb S. Editorial Comment on “Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.” Urology 2015; 85: 170. PMID: 25530380. Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379
Loeb S and Catalona WJ. “Prostate cancer screening: Where are we now?” Contemporary Urology, May 2007 Link:
Loeb S and Catalona WJ. “PSA as a Screening Test for Prostate Cancer.” ACP Observer, April 2007
Loeb S and Catalona WJ. “Advances in Prostate Cancer Testing.” Clinical Laboratory News, March 2007; 33: 12.
Catalona WJ and Loeb S. “PSA Is an Effective Marker for Prostate Cancer.” AUANews, January 2007 (Part 1) and February 2007 (Part 2) Link:
Catalona WJ and Loeb S. “More Effective Use of PSA” Urologic Oncology: Seminars and Original Investigations, May-June 2006; 24: 177.
Loeb S. “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.” Urology August 2011; 78: 255. PMID: 21820566. Link: http://www.ncbi.nlm.nih.gov/pubmed/21820566
Loeb S and Partin AW. “Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.” Reviews in Urology 2011; 13: 63. PMID: 21845110. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/
Makarov DV, Loeb S, Getzenberg RH, and Partin AW. “Biomarkers for Prostate Cancer.” Annual Reviews in Medicine, October 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298
Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ. “Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.” Urologic Oncology: Seminars and Original Investigations, November-December 2006; 24: 465. Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126
Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ. “Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?” BJU International, November 2009; 104: 1200. Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283
Loeb S. “Prostate Biopsy: A Risk-Benefit Analysis.” Journal of Urology, March 2010; 183: 852. Link: http://www.ncbi.nlm.nih.gov/pubmed/20089273
Loeb S. “Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.” Journal of Urology, December 2009; 182: 2701. Link: http://www.ncbi.nlm.nih.gov/pubmed/19836758
Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ. “Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening” Journal of Urology, March 2006; 175: 902. Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. “Overdiagnosis and Overtreatment of Prostate Cancer.” European Urology 2014; epub Jan 9. PMID: 24439788 Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788 This systematic review of epidemiological, clinical and autopsy studies found a very wide of estimates for prostate cancer overdiagnosis from 1.7-67%. Published estimates… Read More
Loeb S. “Does PCA3 Help Identify Clinically Significant Prostate Cancer?” European Urology, July 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556
Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ. “Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening” Journal of Urology, March 2006; 175: 902. Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, and Lotan Y. “Systematic Review of Complications of Prostate Biopsy.” European Urology 2013; June epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/23787356 This systematic review of prostate biopsy complications found that hematuria and hematospermia are most common, but are typically mild and self-limiting. Severe… Read More
Loeb S, Vardi IY, and Nadler RB. “Contemporary Management of Urosepsis: Updated Critical Care Guidelines.” Contemporary Urology, July 2005
Loeb S, Schaeffer EM, and Epstein JI. “The Vanishing Prostate Cancer Phenomenon.” Urology, January 2010 epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/20079526
Loeb S and Catalona WJ. “What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?” Nature Clinical Practice Urology, August 2006; 3: 418. Link: http://www.nature.com/nrurol/journal/v3/n8/full/ncpuro0549.html
Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P. “Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.” Journal of the National Cancer Institute (JNCI) 2013 July epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055 Imaging is very important for staging of high-risk prostate cancer, but is not recommended for low-risk disease…. Read More
Loeb S and Catalona WJ. “Cancer Biomarkers: Discovery and Validation.” Cancer Letters, January 2007
Catalona WJ, Loeb S, and Han M. “Viewpoint: Expanding Prostate Cancer Screening.” Annals of Internal Medicine, March 2006; 144: 441. Link: http://www.ncbi.nlm.nih.gov/pubmed/16549857
Nadler RB, Loeb S, Roehl KA, Antenor JV, Eggener SE, and Catalona WJ. “Use of 2.6 ng/ml Prostate Specific Antigen (PSA) Prompt for Biopsy for Men Over Age 60” Journal of Urology, December 2005; 174: 2154. Link: http://www.ncbi.nlm.nih.gov/pubmed/16280754